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A B S T R A C T
Purpose
Cabozantinib (XL184), an oral inhibitor of multiple receptor tyrosine kinases such as MET and
VEGFR2, was evaluated in a phase II nonrandomized expansion study in castration-resistant
prostate cancer (CRPC).
Patients and Methods
Patients received open-label cabozantinib at daily starting doses of 100 mg or 40 mg until disease
progression or unacceptable toxicity. The primary end point was bone scan response, defined as 
30% reduction in bone scan lesion area. Other efficacy end points included overall survival, pain,
analgesic use, and biomarkers.
Results
One hundred forty-four patients sequentially enrolled in either a 100-mg (n  93) or 40-mg (n  51) study
cohort. Ninety-one patients (63%) had a bone scan response, often by week 6. Treatment resulted in
clinically meaningful pain relief (57% of patients) and reduction or discontinuation of narcotic analgesics
(55% of patients), as well as improvements in measurable soft tissue disease, circulating tumor cells, and
bone biomarkers. Improvements in each of these outcomes were observed in both cohorts: bone scan
response in 73% and 45%, respectively; reductions in measurable soft tissue disease in 80% and 79%,
respectively. Median overall survival was 10.8 months for the entire population. Most common grade 3 or
4 adverse events were fatigue (22%) and hypertension (14%). Fewer dose reductions because of toxicity
were required in the 40-mg group.
Conclusion
The evidence suggests that cabozantinib has clinically meaningful activity in CRPC. Cabozantinib
resulted in improvements in bone scans, pain, analgesic use, measurable soft tissue disease,
circulating tumor cells, and bone biomarkers. Taken together, these phase II observations warrant
further development of cabozantinib in prostate cancer.
J Clin Oncol 32:3391-3399. © 2014 by American Society of Clinical Oncology
INTRODUCTION
Cabozantinib (XL184) is an oral inhibitor of multi-
ple receptor tyrosine kinases, including MET and
vascular endothelial growth factor receptor 2
(VEGFR2). Treatment in multiple tumor xenograft
models, including prostate cancer, results in rapid
induction of both endothelial and tumor cell apo-
ptosis.1 Cabozantinib also has potent effects on the
bone microenvironment, including osteoclast and
osteoblast differentiation in vitro and, at higher con-
centrations, inhibition of osteoblast activity.2 Con-
sistent with these effects, cabozantinib inhibits pro-
gression of both osteoblastic and osteolytic lesions in
xenograft models of metastatic castration-resistant
prostate cancer (CRPC).3,4
A randomized discontinuation trial (RDT) of
cabozantinib suggested a clinically important role for
dual MET/VEGFR inhibition in prostate cancer.5 In
men with metastatic CRPC (n  171), cabozantinib
(100 mg daily) treatment markedly increased
progression-freesurvivalcomparedwithplacebo(haz-
ard ratio, 0.12; P  .001). Cabozantinib was associated
with pain improvement and decreased narcotic
JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T
VOLUME 32  NUMBER 30  OCTOBER 20 2014
© 2014 by American Society of Clinical Oncology 3391
requirements, soft tissue disease, and biomarkers of osteoclast and osteo-
blast activity. In posthoc analyses of patients with bone metastases, cabo-
zantinib resulted in a high rate of rapid and dramatic improvements in
bone scan by visual assessment. Notably, more than 60% of patients
required dose reductions because of adverse effects, similar to what
has been observed with other tyrosine kinase inhibitors that target
VEGFR. A subsequent single-institution dose-ranging study of
men with metastatic CRPC reported bone scan improvements in
most patients treated with cabozantinib at a lower starting dose of
40 mg daily,6 with more modest effects at the lowest dose tested (20
mg daily). Importantly, fewer dose reductions and treatment in-
terruptions were required at lower starting doses.
Whole-body technetium-99 bone scan is a standard imaging
modality for detection and monitoring of bone metastases. Regions of
uptake are an indirect measure of metastatic activity reflecting areas of
newly deposited hydroxyapatite matrix. In contrast to other radiologic
imaging modalities, no accepted standards exist to define a favorable
outcome in bone metastases. Brown et al7 analytically validated a
quantitative biomarker of osseous disease on a technetium-99 bone
scan, bone scan lesion area (BSLA), measured with a fully automated
computer-aided detection system. The software was cleared by the US
Food and Drug Administration and enables reproducible assessments
of changes in individual lesions and total disease burden over time.
We conducted a nonrandomized expansion study of men with
CRPC, bone metastases, and disease progression despite prior treat-
ment with docetaxel (ClinicalTrials.gov trial No. NCT00940225). We
enrolled two cohorts at starting doses of 100 mg and 40 mg daily.
These dose levels were chosen to confirm encouraging but mostly
posthoc observations from the phase II RDT and promising results of
a single-institution dose-finding study. The prespecified primary end
point was bone scan response, defined as at least a 30% improvement
in BSLA. Our article describes the results of these two cohorts.
PATIENTS AND METHODS
Patients
Eligible patients had CRPC and bone metastases on bone scan, East-
ern Cooperative Oncology Group performance status of 0 or 1, and ade-
quate hematologic and end-organ function. All patients had received at
least one previous docetaxel-containing regimen (with cumulative do-
cetaxel exposure  225 mg/m2) and had disease progression (radiographic
disease progression in either soft tissue or bone or radiation treatment of
bone lesion) during or within 6 months of their most recent standard
treatment with a taxane or abiraterone-containing regimen. Patients with
more than three previous chemotherapy regimens, brain metastases, or
clinically significant intercurrent illnesses were excluded. Our study was
conducted in compliance with the Declaration of Helsinki. Institutional
review boards of participating institutions reviewed and approved study
protocol and informed-consent documents. Informed consent was ob-
tained before any study-specified procedures.
Study Design
Our study sequentially enrolled patients in two cohorts: at a 100-mg
starting dose and then at a 39.4-mg (denoted as 40-mg) starting dose. The
prespecified primary end point was bone scan response, defined as an at least
30% reduction in BSLA from baseline as assessed by independent radiology
review. Additional end points included overall survival (OS), pain, use of
analgesic medications, effects on soft tissue, and changes in biomarkers. All
patients received study treatment until disease progression or unaccept-
able toxicity.
Study Drug Administration
Patients received an initial daily starting dose of cabozantinib at 100
mg (first cohort) or 40 mg (second cohort). Treatment was interrupted for
intolerable grade 2 toxicity, grade  3 toxicity of significant clinical risk
despite optimal management, urine protein/creatinine ratio of more than
1, or any grade 4 hematologic toxicity; therapy was restarted if toxicity
resolved to grade  1 or baseline levels within 6 weeks. If the adverse event
was unrelated to study therapy, treatment was resumed with no dose
change. If the adverse event was related to study treatment, patients in the
100-mg cohort resumed at a reduced dose of 60 mg/day, with subsequent
dose reductions to 40 mg/day and 20 mg/day; patients in 40-mg cohort
resumed at a dose of 20 mg/day. Dose interruption for more than 6 weeks
required discontinuation of study treatment.
Study Assessments
Our study followed Prostate Cancer Working Group 2 guidelines, in-
cluding description of results by individual disease manifestations.8
Bone scans. We acquired whole-body PA and AP bone scans using a
Digital Imaging and Communications in Medicine standardized protocol.
When possible, we used the same camera, technetium isotope dose, and delay
from injection to scanning for baseline and follow-up scans. We analyzed bone
scans using a 510(k)-cleared automated computer-aided detection system
(IBIS, MedQIA, Los Angeles, CA) to objectively identify and quantify bone
metastases.7 After image normalization, the software automatically identified
and marked all candidate lesions. Using a locked sequential reading paradigm,
two experienced readers independently reviewed CAD segmentation output.
Readers could accept, modify, remove, or add lesions. Readers also classified
post-treatment bone scans as complete resolution (complete disappearance of
all lesions consistent with bone metastases), partial resolution (clear evidence
of improvement), stable disease (unchanged), or progressive disease (evidence
of two or more new lesions) relative to baseline scans. All readers were blinded
to patients’ clinical and biochemical status.
Bone scan lesion area. For each time point, the system calculated BSLA
and percentage change in BSLA between each time point and baseline scan.
We defined bone scan outcomes based on change from baseline as follows:
response was  30% reduction in lesion area; progressive disease was  30%
increase in lesion area (or two new lesions); stable disease was any change not
categorized as response or progressive disease.7
Overall survival. OS was defined as time from first dose until date of
death as a result of any cause or censoring at last date known alive at time of
data analysis cutoff.
PSA, CTCs, hemoglobin and reticulocytes, and bone turnover markers.
Additional outcomes included serum prostate-specific antigen (PSA), circu-
lating tumor cells (CTCs), hemoglobin, reticulocyte count, and bone bio-
markers (serum N-terminal cross-linked telopeptides of type I collagen [NTx],
C-terminal cross-linked telopeptides of type I collagen [CTx], and bone-
specific alkaline phosphatase [BSAP]).
Pain assessments. Patients reported daily their worst pain (via Interac-
tive Voice Response System) and analgesic medication usage (via diary) during
7-day intervals (at least four of seven days) at screening, week 3, week 6, and
every 6 weeks thereafter.
Clinical assessments. Clinical assessments included medical and cancer
history, physical examination, vital signs, body weight, electrocardiography,
Eastern Cooperative Oncology Group performance status, laboratory analyses
(serum chemistry, hematology [including reticulocyte counts], coagulation,
urinalysis, testosterone), concomitant medications, adverse events, and infor-
mation on subsequent anticancer treatment.
Sample analyses. Blood samples for CTC analysis were collected in
CellSave tubes, and enumeration was performed using CellSearch assay9 at
Veridex (Huntingdon Valley, PA and Beerse, Belgium) or Memorial Sloan-
Kettering Cancer Center Clinical Chemistry Laboratory (New York, NY).
Bone biomarkers were assessed at Covance Central Laboratories (NTx: Osteo-
mark NTx serum competitive inhibition ELISA kit, Wampole Laboratories,
Princeton, NJ; CTx: Crosslaps ELISA, Immunodiagnostic Systems AC-02F1
Immunodiagnostic Systems, Scottsdale, AZ; BSAP: Ostase assay, Beckman
Coulter, Brea, CA). For patients with measurable CTx/NTx at baseline whose
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postbaseline values dropped below the lower limit of quantitation, the lower
limit of quantitation was used in calculations of postbaseline effects.
Statistical Methods and Considerations
The study was designed to enroll a sufficient number of patients to
estimate changes in multiple outcome measures rather than focus on a single
outcome measure. A sample size of 150 patients at the 100-mg dose level was
originally chosen to permit estimation of changes in each outcome with con-
fidence intervals of no more than 16 percentage points. The protocol was
subsequently amended to include a 40-mg dose level using the same total
sample size of 150 patients.
Study outcomes including prespecified bone scan response were sum-
marized for overall population and each cohort. Time-to-event outcomes
were analyzed using Kaplan-Meier plots and summaries.
RESULTS
Patients and Treatment
From February 2011 to April 2012, 144 CRPC patients with bone
metastases in the United States and United Kingdom were sequen-
tially enrolled into 100-mg (n  93) and 40-mg cohorts (n  51).
Baseline demographic and clinical characteristics are listed in Table 1.
All but one patient had radiographic progression within 6 months of
their last taxane dose. For the overall study population, 44% and 24%
had received prior abiraterone and cabazitaxel, respectively. Zole-
dronic acid or denosumab treatment at baseline was reported in 63%
of patients. Compared with the 100-mg cohort, patients in the 40-mg
cohort had higher rates of prior abiraterone treatment (65% v 32%)
and disease progression within 1 month of last taxane dose (49%
v 29%).
Figure 1 summarizes patient disposition as of data cutoff. Median
time on treatment was 4.4 months (range, 0.8 to 16.4) for the 100-mg
cohort and 4.2 months (range, 0.3 to 9.1) for the 40-mg cohort.
Progressive disease or clinical deterioration was the most common
reason for treatment discontinuation in both cohorts. The median
average daily dose received by patients in 100-mg and 40-mg cohorts
was 55 mg and 36 mg, respectively.
Bone Scan Outcomes by Independent Radiology
Review
Ninety-one patients (63%) had a prespecified bone scan re-
sponse ( 30% reduction in BSLA), 27 patients (19%) had stable
disease, and 14 patients (10%) had progressive disease as best bone
scan outcome (Table 2). Figure 2A illustrates percentage change in
BSLA in patients evaluable for BSLA changes. Median bone scan
response duration was 5.2 months (range,  0.03 to  13.9 months;
Table 2). Bone scan response rate was higher in the 100-mg cohort
than the 40-mg cohort (73% v 45%). Improvements in bone scans
were rapid, with most patients categorized as responders at week 6
(first time point). Reader-determined visual responses and CAD-
calculated changes in BSLA were concordant (overall Kappa  0.8).
Measurable Disease Outcomes
Among 54 patients with measurable soft tissue disease at baseline
and at least one adequate postbaseline assessment, 43 patients (80%)
had reduction in measurable disease at one or more assessments (Fig
2B). Rates of improvement in measurable disease were similar for the
100-mg and 40-mg cohorts (80% v 79%).
Bone Pain and Narcotic Use
At baseline, 68 men (47%) reported moderate to severe pain
(defined as an average worst pain score  4 on the 11-point (0-10)
brief pain inventory scale; Table 1). Among these men, 65 had at least













Median 66 65 65
Range 46-85 43-83 43-85
ECOG status, %
0 34 35 35
1 65 65 65
2 1 0 1
Sites of disease, %
Bone 100 100 100
Visceral 31 33 32
Measurable disease, % 41 41 41
Pain score  4, % 44 53 47
Pain score  4 and narcotics, % 42 45 43
Fatigue any grade, % 54 57 55
 Two prior regimens for mCRPC, % 73 73 73
Prior therapies, %
Docetaxel 100 100 100
Abiraterone 32 65 44
Cabazitaxel 24 25 24
Enzalutamide 4 4 4
Radionuclide† 5 6 6
Bone agents, %‡ 62 63 63
Time to progression from last taxane
dose, %§
 1 month 29 49 36
1-6 month 71 49 63
PSA, ng/mL
Median 194 146 188
Range 0.2-2,990 9-2,428 0.2-2,990
CTC count per 7.5 mL blood
Median 49 25 37
Range 0-1,659 0-3,959 0-3,959
Hemoglobin, g/dL¶
Median 11.8 11.5 11.6
Range 8.5-17.1 8.5-14.5 8.5-17.1
Reticulocyte counts, %¶
Median 1.8 2.1 1.9
Range 0.8-4.5 0.9-3.9 0.8-4.5
LDH, %
 ULN 56 59 57
 ULN 44 39 42
NOTE. Percentages may not add up to 100% because of rounding.
Abbreviations: CAD, computer-aided detection; CRPC, castration-resistant
prostate cancer; CTC, circulating tumor cell; ECOG, Eastern Cooperative
Oncology Group; LDH, lactate dehydrogenase; mCRPC, metastatic castration-
resistant prostate cancer; PSA, prostate-specific antigen; ULN, upper limit of
normal.
Baseline bone scans for 49 of 51 patients (40-mg dose cohort) and 92 of 93
patients (100-mg dose cohort) reported to have bone metastases by the
investigator were evaluable by CAD.
†Includes one patient in the 100-mg dose cohort who had prior alpharadin.
‡Zoledronic acid or denosumab at baseline (includes two patients who
discontinued zoledronic acid within 60 days before first dose of cabozantinib).
§Not applicable for one patient in the 40-mg dose cohort.
¶Restricted to patients who did not require transfusion or erythropoietin
treatment while on study (as analyzed in Table 2).
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one adequate postbaseline pain assessment and were evaluated for
pain responses (Table 2). Forty-four (68%) of the 65 men reported a
pain decrease of at least 30% as their best change (Fig 2C); 37 men
(57%) had clinically meaningful pain relief at two consecutive
assessments ( 30% reduction from baseline; Table 2),10 with the
majority at least 6 weeks apart. Similar effects on pain were ob-
served in both cohorts (Table 2; Fig 2C). Reductions in narcotics
occurred in 55% of patients, including discontinuation of narcot-
ics in 13 patients (Table 2). Pain palliation occurred as early as first
pain assessment at week 3 (data not shown); detailed analyses on
pain and narcotics use in these patients are described elsewhere
(Basch et al11).
Biomarkers
Circulating tumor cells. Post-treatment changes in CTC counts
were assessed in 103 patients with baseline unfavorable CTC counts
( 5 per 7.5 mL blood) and at least one follow-up assessment at week
6 or 12 (Table 2). At week 6, 30% of patients converted from unfavor-
able to favorable CTC counts ( 5 per 7.5 mL blood). Eighty-two
percent of patients had a decrease of at least 30% in CTCs at week 6
and/or 12. Changes were similar for both cohorts. Best change in
CTCs at week 6 and/or 12 for patients with baseline CTCs  5 is
illustrated for each cohort in Figure 3A. CTC outcomes were not
related to prior cancer therapy (data not shown).
Prostate-specific antigen. Among 131 patients with baseline and
at least one postbaseline PSA assessment, 14 patients (11%) had a
decrease of at least 50% in PSA from baseline as best change (Table 2).
Hemoglobin and reticulocyte counts. RBC transfusions or
erythropoietin-based growth factor therapy were required in 27 of 144
patients. Effects on hemoglobin and reticulocyte counts were evalu-
ated in patients who did not require these interventions; median
maximum increases in hemoglobin levels and reticulocyte count were
1.4 g/dL (range, 1.3 to 3.7 g/dL) and 0.2% (range, 1.7% to 2.6%),
respectively. The largest increases in both hemoglobin and reticulo-
cytes were observed in patients with baseline hemoglobin levels below
median value (Table 2).
Bone biomarkers. We analyzed biomarkers of bone metabolism
(NTx, CTx, BSAP) in serially collected serum samples. Among pa-
tients with at least one follow-up assessment, median changes in CTx
from baseline to week 12 were 37% and 31% decreases for the 100-
and 40-mg cohorts, respectively (Fig 3B and Table 2). We observed
similar changes for NTx (data not shown). Modulations of BSAP were
also evident, with 72% and 50% of patients showing a decrease at week
12 or later for the 100- and 40-mg cohorts, respectively (Fig 3C and
Table 2). We observed changes in bone biomarkers regardless of prior
bisphosphonate or denosumab therapy (data not shown).
Overall Survival
Median OS in the overall study population was 10.8 months
(95% CI, 9.1 to 13.0). Median OS was 12.1 months (95% CI, 9.4 to
14.3) and 9.1 months (95% CI, 8.0 to 12.9) in the 100-mg and 40-mg
cohorts, respectively.
Safety
The most frequent adverse events reported regardless of attribu-
tion are listed in Table 3. All patients experienced at least one adverse
event and most patients experienced more than one event. The most
common grade  3 events in all patients, regardless of causality, were
fatigue (22%), hypertension (14%), anemia (13%), and pulmonary
embolism (11%). Rate of grade  3 pulmonary embolism was 8% in
the 100-mg cohort and 18% in 40-mg cohort. One patient in the
100-mg cohort who had extensive liver involvement experienced a
related grade 3 portal vein thrombosis with grade 5 liver failure.
In the 100-mg cohort, 84% of patients had at least one dose
reduction and 25% discontinued treatment because of an adverse
event. Median time to first dose reduction for the 100-mg cohort was
32 days (range, 5 to 170 days). In the 40-mg cohort, 31% of patients
had at least one dose reduction because of an adverse event and 18% of
patients discontinued treatment because of an adverse event. These
different rates of dose reduction resulted in a lower dose intensity
(administered dose/intended dose) for the 100-mg cohort (55%)
compared with the 40-mg cohort (90%). Median average daily doses
received in the 100-mg and 40-mg cohorts was 55 mg/day and 36
mg/day, respectively.
DISCUSSION
In this multicenter, phase II, nonrandomized expansion study of men
with CRPC, bone metastases, and disease progression despite docetaxel
treatment,cabozantinibwasassociatedwithimprovementsinbonescans,
patient-reported pain and analgesic use, measurable disease, CTCs, and
bone biomarkers. Taken together, these observations suggest that cabo-
zantinib (at doses as low as 40 mg daily) is biologically active in metastatic
CRPC and support its further development in prostate cancer.
Results of this study extend observations from the previously
reported RDT that cabozantinib improves a variety of disease-related
outcomes in patients with metastatic CRPC.5 In contrast to the RDT,
100-mg cabozantinib cohort
(N = 93)
Median (range) duration of treatment: 
4.4 months (0.8–16.4 months)
Active
(n = 1; 1.1%)
Discontinued (n = 92; 98.9%)
  Progressive disease/ (n = 65; 69.9%)
    clinical deterioration
  Adverse event (n = 23; 24.7%)
  Patient request (n = 3; 3.2%)
  Investigator decision (n = 1; 1.1%)
40-mg cabozantinib cohort
(N = 51)
Median (range) duration of treatment: 
4.2 months (0.3–9.1 months)
Active
(n = 13; 25.5%)
Discontinued (n = 38; 74.5%)
  Progressive disease/ (n = 26; 51.0%)
    clinical deterioration
  Adverse event (n = 9; 17.6%)
  Patient request (n = 2; 3.9%)
  Investigator decision (n = 1; 2.0%)
A
B
Fig 1. Patient disposition as of data cutoff point for this report.
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however, patients in our current study had greater disease burden,
more pain and narcotic requirements, and more extensive prior ther-
apy. Notably, all patients in our current study had bone metastases and
disease progression despite prior docetaxel treatment. Accordingly,
patients in our current study had a worse prognosis than patients
enrolled onto the RDT and most other contemporary studies of met-
astatic CRPC. Improvements in a variety of disease-related outcomes
in this heavily treated population suggest that cabozantinib does not
share mechanism(s) of resistance with other prostate cancer treat-
ments including docetaxel, cabazitaxel, and abiraterone. The apparent
nonoverlapping resistance between cabozantinib and other agents
may reflect targeting of tumor, stroma, and tumor-stroma interac-
tions by cabozantinib.
Two ongoing randomized controlled trials will further evaluate
the efficacy and safety of cabozantinib in mCRPC. COMET-1 (clini-
caltrials.gov identifier: NCT01605227) compares cabozantinib with
prednisone; the primary end point is OS. COMET-2 (clinicaltrials.gov
identifier: NCT01522443) compares cabozantinib with mitoxantrone
Table 2. Responses to Treatment
End Point
100-mg Cabozantinib
Cohort (n  93)
40-mg Cabozantinib
Cohort (n  51) Total (N  144)
No. of Patients % No. of Patients % No. of Patients %
Bone scan
Response rate, primary end point 68 73 23 45 91 63
Partial response 69 43 60
Complete response 4 2 3
Stable disease 12 31 19
Progressive disease† 8 14 10
Duration of response in months‡
Median 5.2 NR 5.2
Range  0.03- 13.9 1.4- 6.9  0.03- 13.9
Pain and narcotics use in patients with baseline pain score  4
No. of evaluable patients 39 26 65
Median best change, % reduction 46 49 46
Pain response§ 22 56 15 58 37 57
Decreased narcotics use at any time point¶ 22 56 14 54 36 55
CTCs in patients with baseline  5 per 7.5 mL blood
No. of patients evaluable for changes at week 6 and/or 12 64 39 103
Median CTC count, n 80 36 66
Converted to  5 per 7.5 mL blood at week 6 34 23 30
At least 30% reduction at week 6 and/or 12 91 67 82
Median change from baseline, % decrease 86 70 84
CTCs in patients with baseline  5 per 7.5 mL blood
No. of patients evaluable for changes at week 6 and/or 12 17 10 27
Converted to  5 per 7.5 mL blood at week 6 and/or 12 18 10 15
PSA
No. of patient evaluable 86 45 131
 50% reduction, best change from baseline 13 7 11
Hemoglobin changes independent of transfusion or erythropoietin
Median maximal increase in evaluable patients, g/dL 1.4 1.2 1.4
Median maximal increase in patients with baseline hemoglobin  median 1.7 1.5 1.5
Reticulocyte changes independent of transfusion or erythropoietin
Median maximal increase in evaluable patients 0.2 0.1 0.2
Median maximal increase in patients with baseline hemoglobin  median 0.3 0.3 0.3
Bone turnover markers
No. of patients evaluable for CTx changes at week 12 50 16 66
Median change at week 12, % reduction 37 31 34
No. of patients evaluable for BSAP changes at week 12 or later 74 38 112
Percentage of patients with a decrease at week 12 or later 72 50 64
NOTE. Percentages may not total 100% because of rounding.
Abbreviations: BSAP, bone-specific alkaline phosphatase; CAD, computer-aided detection; CTC, circulating tumor cell; CTx, C-terminal cross-linked telopeptides of
type I collagen; NR, not reached as of data cutoff point; PSA, prostate-specific antigen.
Complete responders plus partial responders. Complete response is defined as 100% reduction of bone scan lesion area; partial response is defined as  30%
reduction of bone scan lesion area. Of the 144 men enrolled onto the study, 132 (100-mg cohort, 86 patients; 40-mg cohort, 46 patients) had bone metastases on
baseline bone scan and at least one evaluable post-baseline scan for bone scan response per CAD.
†Two or more new areas of uptake or unequivocal increase of uptake at metastatic sites.
‡In the 100-mg cohort, 68 patients were evaluated and, in the 40-mg cohort, 23 were evaluated for a total of 91 patients.
§At least a 30% reduction from baseline in average worst pain score measured at two consecutive assessments, which includes eight patients whose consecutive
assessments were at weeks 3 and 6. For the remaining patients, the two consecutive assessments were at least 6 weeks apart.
¶Includes patients who discontinued narcotics at any time point (40-mg cohort, n  1; 100-mg cohort, n  12). Equianalgesia calculations were used to determine
changes in narcotics use for patients who modified narcotics types throughout the assessments.
Phase II Nonrandomized Expansion Study of Cabozantinib in CRPC
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plus prednisone in patients with symptomatic disease; the primary
end point is pain response. Both studies include patients with bone
metastases and disease progression after docetaxel and either abi-
raterone or enzalutamide.
Ours is the first multicenter study to use prespecified bone scan
response as the primary study outcome. The results demonstrate the
potential for CAD-based quantitative bone scan as a dynamic assess-
ment of bone metastases. Notably, the COMET-1 and COMET-2
phase III studies include CAD-based quantitative bone scan outcomes
as secondary end points, which will provide the opportunity to criti-
cally evaluate relationships between bone scan outcomes and clinical
outcomes including pain response and OS.
Outcomes for the 100-mg and 40-mg cohorts are not directly
comparable because the study was not randomized and there were
important differences in baseline characteristics between sequen-
tially enrolled cohorts. Furthermore, the median average daily dose
in the 100-mg cohort was 55 mg/day, further minimizing the true
difference in actual dose administered between cohorts. These















































































Fig 2. (A) Bone scan lesion area. Best change from baseline in bone scan lesion
area in the 132 patients evaluable for the primary end point (100-mg cohort, n 
86; 40-mg cohort, n  46), bone scan response (Table 2). Median change in bone
scan lesion area was a 49% reduction. The dashed line denotes a 30% reduction
defined as bone scan response by computer-aided detection (CAD; Table 2).
Values higher than 100% are represented as 100% because of y axis truncation
at 100%; (), increases greater than 100%. (B) Soft tissue lesions. Best change
from baseline in soft tissue lesions in 54 patients (100-mg cohort, n  35; 40-mg
cohort, n  19) with measurable disease at baseline and  1 postbaseline
assessment. Median change in sum of longest diameter was a 17% reduction.
Stable disease per Response Evaluation Criteria in Solid Tumors is represented
by the space between the dashed lines. (C) Pain. Best change from baseline in
average worst pain in patients with baseline score  4 (100-mg cohort, n  39;
40-mg cohort, n  26) and at least one adequate postbaseline assessment. The





















































































Fig 3. (A) Circulating tumor cells (CTCs). Best change from baseline in CTCs in
patients with at least five baseline CTCs and week 6 and/or week 12 assessment
(100-mg cohort, n  64; 40-mg cohort, n  39). (B) C-terminal cross-linked
telopeptides of type I collagen (CTx). Percentage change from baseline for serum
CTx at week 12 (100-mg cohort, n  50; 40-mg cohort, n  16). (C) Bone-specific
alkaline phosphatase (BSAP). Best change from baseline for serum BSAP at
week 12 or later (100-mg cohort, n  74; 40-mg cohort, n  38). Values higher
than 100% are represented as 100% because of y axis truncation at 100%; (),
denotes increases greater than 100%.
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No new or unexpected adverse events were observed in our
study. The rate for pulmonary embolus was somewhat higher than
previously described in patients with metastatic CRPC.5 Notably,
there are no reliable historical references for the expected rate of
thromboembolic events in this patient population. The frequent
imaging schedule (every 6 weeks) might have identified some
asymptomatic pulmonary emboli and could have contributed to a
higher than expected event rate. Importantly, the ongoing phase III
studies will characterize the rates of treatment-related adverse
events. Compared with patients treated at a starting dose of 100
mg, those who received 40 mg in our current study had lower rates
of dose reduction or drug discontinuation because of an adverse
event. These observations are consistent with reported tolerability
from a single-institution dose-ranging study of cabozantinib in
patients with metastatic CRPC.6
In summary, the totality of the evidence suggests that cabozan-
tinib is biologically active in metastatic CRPC. In men with CRPC,
bone metastases, and disease progression despite prior docetaxel treat-
ment, cabozantinib was associated with improvements in a variety of
disease-related outcomes including bone scans, pain and analgesic
use, measurable disease, CTCs, and bone biomarkers.
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Table 3. Most Frequently Reported Adverse Events Regardless of Causality
Adverse Event
All Grades Grade  3
100-mg Cabozantinib
Cohort (n  93)
40-mg Cabozantinib
Cohort (n  51)
100-mg Cabozantinib
Cohort (n  93)†
40-mg Cabozantinib
Cohort (n  51)
No. of Patients % No. of Patients % No. of Patients % No. of Patients %
Fatigue 77 83 32 63 25 27 7 14
Decreased appetite 70 75 23 45 7 8 4 8
Nausea 67 72 29 57 11 12 0 0
Diarrhea 66 71 22 43 11 12 1 2
Decrease in weight 42 45 19 37 6 6 0 0
Vomiting 38 41 18 35 4 4 0 0
Dysgeusia 35 38 14 27 0 0 0 0
Dysphonia 34 37 9 18 0 0 1 2
Constipation 33 35 16 31 4 4 2 4
Dyspnea 30 32 13 25 6 6 1 2
Hypothyroidism 30 32 4 8 0 0 0 0
Arthralgia 29 31 6 12 4 4 2 4
Back pain 29 31 15 29 10 11 5 10
Anemia 28 30 7 14 16 17 3 6
Pain in extremity 28 30 12 24 4 4 1 2
Palmar-plantar erythrodysesthesia syndrome 24 26 7 14 5 5 0 0
Hypertension 23 25 10 20 14 15 6 12
Dehydration 22 24 5 10 7 8 1 2
Musculoskeletal pain 21 23 7 14 3 3 1 2
Rash 19 20 6 12 0 0 0 0
NOTE. Adverse events were  20% for all grades in the 100-mg cohort.
MedDRA (Medical Dictionary for Regulatory Activities) version 15.1 preferred terms, based on Common Terminology Criteria for Adverse Events version 3.0.
†One patient in the 100-mg cohort who had extensive liver disease experienced a related grade 3 portal vein thrombosis with grade 5 liver failure.
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GLOSSARY TERMS
apoptosis: also called programmed cell death. Apoptosis is a
signaling pathway that leads to cellular suicide in an organized
manner. Several factors and receptors are specific to the apopto-
tic pathway. The net result is that cells shrink and develop blebs
on their surface, and their DNA undergoes fragmentation.
circulating tumor cells: demonstration of isolated tumor
cell circulation/dissemination in the peripheral blood.
MET: the receptor for hepatocyte growth factor. MET is a trans-
membrane receptor tyrosine kinase. The primary single chain
precursor protein is post-translationally cleaved to produce the
alpha and beta subunits; the mature receptor is composed of
these subunits linked via disulfide bonds. Various mutations in
the MET gene have been associated with papillary renal
carcinoma.
osteoclast: a cell that breaks down bone and is responsible for bone
resorption. Osteoclasts are large multinucleate cells that differentiate
from macrophages.
receptor tyrosine kinase: transmembrane protein with intrinsic
ability to transfer phosphate groups to tyrosine residues contained in
cellular substrates. See tyrosine kinase receptors.
VEGFR (vascular endothelial growth factor receptor):
transmembrane tyrosine kinase receptors to which the VEGF ligand
binds. VEGFR-1 (also called FLT1) and VEGFR-2 (also called KDR/
FLK1[murine homologue]) are expressed on endothelial cells, whereas
VEGFR-3 (also called FLT4) is expressed on cells of the lymphatic and
vascular endothelium. VEGFR-2 is thought to be principally responsible
for angiogenesis and for the proliferation of endothelial cells. Typically,
most VEGFRs have seven extracellular immunoglobulin-like domains,
responsible for VEGF binding, and an intracellular tyrosine kinase
domain.
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